A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Recap by typeshit. Post by @boxlifemagazine on Instagram.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
The retatrutide rival from United Biotechnology led to weight loss of up to 9.8% at 24 weeks in 211 Chinese adults, beating semaglutide's 4.8%, per Cell Metabolism.
The think tank argues regulated compounding beats 'research use only' sellers, noting an FDA panel voted to add six peptides despite staff advising against all seven.
NSW peptide hospitalisations went from five in July 2025 to over 200 in September 2026, and needle programs say syringe machines are emptying within hours.
Loading…